---
input_text: "Longitudinal Assessment of Macular Thickness and Microvascular Changes
  in Children with Sickle Cell Disease.PURPOSE: To longitudinally assess macular thickness
  and microvascular changes in children with sickle cell disease (SCD). DESIGN: A
  retrospective consecutive series. SUBJECTS: Children with SCD aged 18 years old
  or less who had an ophthalmic exam at Boston Children's Hospital between January
  1998 and August 2022. METHODS: Qualitative and quantitative analyses of both optical
  coherence tomography (OCT) and OCT angiography (OCTA) images were performed. MAIN
  OUTCOME MEASURES: Total retinal thickness measured on macular OCT, as well as superficial
  capillary plexus (SCP) and deep capillary plexus (DCP) vessel density (VD), and
  foveal avascular zone (FAZ) area measured on 6 x 6 mm OCTA scans. RESULTS: ICD-10
  code search identified 303 pediatric SCD patients who underwent ophthalmic exam
  during the study period. OCT and OCTA images were acquired on 104 (17.2%) and 60
  (9.9%) eyes at presentation and on 159 (26.2%) and 100 (16.5%) eyes at final visit.
  Overall, temporal retinal thinning was noted qualitatively in 35.6% of SCD patients
  at presentation and 39.6% at final visit. Of those patients with macular thinning,
  94.6% and 90.5% had peripheral sickle cell retinopathy (SCR) at presentation and
  final visit. On quantitative OCT analysis, HbSS eyes had a lower retinal thickness
  in the fovea and temporal parafovea compared with HbSC, P < 0.05. Eyes with peripheral
  SCR had a larger FAZ at presentation compared to eyes without peripheral SCR (P
  = 0.004), a lower DCP VD at final visit in the inferior temporal macula (P = 0.03),
  and a higher DCP VD at final visit in the superior nasal macula (P = 0.01). 80 eyes
  of 40 patients had OCT and 34 eyes of 20 patients had both OCT and OCTA images acquired
  at both initial and final visits. At final visit, retinal thickness decreased at
  the fovea, inferior perifovea, and temporal perifovea compared to presentation,
  P < 0.05. In parallel, VD DCP in the superonasal quadrant increased at final visit,
  P = 0.03. CONCLUSIONS: Macular retinal thinning was progressive and observed in
  eyes with and without peripheral SCR. Over time, there was a compensatory increase
  in DCP VD in the nasal macula on OCTA."
raw_completion_output: |-
  primary_disease: Sickle Cell Disease (SCD)

  medical_actions: Optical coherence tomography (OCT); OCT angiography (OCTA)

  symptoms: Macular retinal thinning; Temporal retinal thinning; Peripheral sickle cell retinopathy (SCR); Lower retinal thickness in the fovea; Lower retinal thickness in the temporal parafovea; Larger foveal avascular zone (FAZ); Lower deep capillary plexus (DCP) vessel density at final visit in the inferior temporal macula; Higher DCP vessel density at final visit in the superior nasal macula

  chemicals: 

  action_annotation_relationships: Optical coherence tomography (OCT) ASSESSES macular retinal thinning IN Sickle Cell Disease (SCD); OCT angiography (OCTA) ASSESSES macular retinal thinning IN Sickle Cell Disease (SCD); Optical coherence tomography (OCT) ASSESSES temporal retinal thinning IN Sickle Cell Disease (SCD); OCT angiography (OCTA) ASSESSES peripheral sickle cell retinopathy (SCR) IN Sickle Cell Disease (SCD); Optical coherence tomography (OCT) ASSESSES lower retinal thickness in the fovea IN Sickle Cell Disease (SCD); Optical coherence tomography (OCT) ASSESSES lower retinal thickness in the temporal parafovea IN Sickle Cell Disease (SCD); OCT angiography (OCTA) ASSESSES larger foveal avascular zone (FAZ) IN Sickle Cell Disease (SCD); OCT angiography (OCTA) ASSESSES lower deep capillary plexus (DCP) vessel density at final visit in the inferior temporal macula IN Sickle Cell Disease (SCD); OCT angiography (OCTA) ASSESSES higher deep capillary plexus (DCP) vessel density at final visit in the superior nasal macula IN Sickle Cell Disease (SCD)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  OCT angiography (OCTA) ASSESSES higher deep capillary plexus (DCP) vessel density at final visit in the superior nasal macula IN Sickle Cell Disease (SCD)

  ===

extracted_object:
  primary_disease: MONDO:0007374
  medical_actions:
    - MAXO:0000969
    - OCT angiography (OCTA)
  symptoms:
    - Macular retinal thinning
    - Temporal retinal thinning
    - Peripheral sickle cell retinopathy (SCR)
    - Lower retinal thickness in the fovea
    - Lower retinal thickness in the temporal parafovea
    - Larger foveal avascular zone (FAZ)
    - Lower deep capillary plexus (DCP) vessel density at final visit in the inferior
      temporal macula
    - Higher DCP vessel density at final visit in the superior nasal macula
  action_annotation_relationships:
    - subject: MAXO:0000969
      predicate: ASSESSES
      object: macular retinal thinning
      qualifier: MONDO:0007374
    - subject: <OCT angiography (OCTA)>
      predicate: <ASSESSES>
      object: <macular retinal thinning>
      qualifier: MONDO:0007374
      subject_qualifier: <None>
      object_qualifier: <None>
      subject_extension: <None>
      object_extension: <None>
    - subject: MAXO:0000969
      predicate: ASSESSES
      object: temporal retinal thinning
      qualifier: MONDO:0011382
    - subject: <OCT angiography>
      predicate: <ASSESSES>
      object: <peripheral sickle cell retinopathy>
      qualifier: <Sickle Cell Disease>
      subject_extension: <OCT angiography>
    - subject: <Optical coherence tomography>
      predicate: <ASSESSES>
      object: <lower retinal thickness in the fovea>
      qualifier: <Sickle Cell Disease>
      subject_qualifier: <Not applicable>
      object_qualifier: <Not applicable>
      subject_extension: <Not applicable>
      object_extension: <Not applicable>
    - subject: <Optical coherence tomography>
      predicate: <ASSESSES>
      object: <retinal thickness in the temporal parafovea>
      qualifier: <Sickle Cell Disease>
      subject_qualifier: <>
      object_qualifier: <>
      subject_extension: <Optical coherence tomography>
      object_extension: <lower>
    - subject: OCT angiography (OCTA)
      predicate: ASSESSES
      object: larger foveal avascular zone (FAZ)
      qualifier: MONDO:0007374
    - subject: <OCT angiography (OCTA)>
      predicate: <ASSESSES>
      object: <lower deep capillary plexus (DCP) vessel density at final visit in
        the inferior temporal macula>
      qualifier: MONDO:0007374
      subject_extension: <OCT angiography (OCTA)>
    - subject: OCT angiography (OCTA)
      predicate: ASSESSES
      object: higher deep capillary plexus (DCP) vessel density
      qualifier: MONDO:0007374
      object_qualifier: at final visit in the superior nasal macula
named_entities:
  - id: MONDO:0011382
    label: sickle cell disease
  - id: MONDO:0100096
    label: SARS-CoV-2
  - id: MONDO:0007374
    label: Sickle cell disease (SCD)
  - id: HP:0100602
    label: Preeclampsia
  - id: HP:0001511
    label: Intrauterine growth restriction
  - id: CHEBI:44423
    label: Hydroxyurea (HU)
  - id: CHEBI:35143
    label: Haemoglobin (Hb)
  - id: HP:0001622
    label: Preterm delivery
  - id: CHEBI:50858
    label: corticosteroids
  - id: HP:0032654
    label: Endothelial dysfunction
  - id: HP:0012418
    label: Hypoxia
  - id: HP:0001409
    label: Portal hypertension
  - id: MAXO:0001001
    label: Gene therapies
  - id: MAXO:0000756
    label: Transfusion
  - id: MAXO:0000747
    label: Hematopoietic stem cell transplantation
  - id: MAXO:0001298
    label: therapy
  - id: MAXO:0009047
    label: Total hip replacement (THR)
  - id: CHEBI:22720
    label: Benzodiazepines
  - id: MONDO:0006079
    label: Acute chest syndrome (ACS)
  - id: CHEBI:24859
    label: Iodine
  - id: MONDO:0005632
    label: Acute chest syndrome
  - id: CHEBI:17334
    label: penicillin
  - id: MAXO:0000118
    label: immunizations
  - id: HP:0001903
    label: anemia
  - id: HP:0001297
    label: stroke
  - id: HP:0012532
    label: Chronic pain
  - id: CHEBI:3216
    label: Buprenorphine
  - id: HP:0001518
    label: Low birth weight
  - id: MAXO:0001006
    label: Full blood count
  - id: MAXO:0000825
    label: Reticulocyte count
  - id: MAXO:0000427
    label: Brain magnetic resonance imaging (MRI)
  - id: HP:0012592
    label: albuminuria
  - id: HP:0100543
    label: cognitive dysfunction
  - id: HP:0000739
    label: anxiety
  - id: HP:0010783
    label: Redness
  - id: CHEBI:33281
    label: antibiotics
  - id: MONDO:0009693
    label: Multiple Myeloma
  - id: CHEBI:145536
    label: Motixafortide
  - id: CHEBI:114786
    label: sodium metabisulfite
  - id: CHEBI:15365
    label: aspirin
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0012622
    label: CKD
  - id: MAXO:0000969
    label: optical coherence tomography (OCT)
  - id: HP:0000505
    label: visual impairment
  - id: CHEBI:28901
    label: busulfan
  - id: CHEBI:82557
    label: treosulfan
  - id: CHEBI:9570
    label: thiotepa
  - id: HP:0100603
    label: Hypertensive disorder of pregnancy (HDP)
  - id: CHEBI:26308
    label: unweighted polygenic risk score (PRS)
  - id: CHEBI:35480
    label: Analgesics
  - id: HP:0012213
    label: Decreased glomerular filtration rate
  - id: HP:0012398
    label: Peripheral oedema
  - id: HP:0001685
    label: Cardiac fibrosis
  - id: MONDO:0005570
    label: hematologic diseases
  - id: HP:0001871
    label: hematologic diseases
  - id: HP:0001712
    label: Left ventricular hypertrophy
  - id: HP:0007760
    label: SCD
  - id: MAXO:0000149
    label: Hematopoietic cell transplant (HCT)
  - id: MAXO:0010203
    label: Echocardiography
  - id: HP:0012531
    label: Pain
  - id: CHEBI:51371
    label: muscle relaxants
  - id: HP:0002140
    label: Arterial ischemic stroke
  - id: MONDO:0019402
    label: Thalassemia major
  - id: MAXO:0000536
    label: Chorionic villus sampling (CVS)
  - id: MONDO:0020380
    label: Sickle cell anemia (SCA)
  - id: MONDO:0005161
    label: Human papillomavirus (HPV) infection
  - id: MAXO:0000759
    label: HPV vaccination
  - id: MAXO:0000447
    label: Surgical removal
  - id: HP:0033138
    label: Right atrial thrombus
  - id: HP:0000989
    label: pruritus
  - id: MAXO:0010041
    label: skin grafting
  - id: MAXO:0000058
    label: Pharmacotherapies
  - id: HP:0001513
    label: obesity
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: HP:0002617
    label: vasculopathy
  - id: MAXO:0000068
    label: Transplantation
  - id: HP:0004870
    label: chronic hemolytic anemia
  - id: CHEBI:27690
    label: acetazolamide
  - id: CHEBI:22984
    label: Calcium
  - id: MAXO:0001479
    label: allogeneic hematopoietic stem cell transplantation
  - id: CHEBI:18050
    label: L-glutamine
  - id: MAXO:0001175
    label: liver transplantation
  - id: HP:0000952
    label: jaundice
  - id: HP:0025637
    label: vasospasm
  - id: CHEBI:125354
    label: plerixafor
  - id: MAXO:0001017
    label: Vaccination
  - id: MONDO:0002492
    label: Acute kidney injury
  - id: HP:0002240
    label: Hepatomegaly
  - id: HP:0001744
    label: Splenomegaly
  - id: HP:0000790
    label: Hematuria
  - id: HP:0001919
    label: Acute kidney injury
  - id: MONDO:0006515
    label: Acute Pancreatitis
  - id: HP:0002155
    label: hypertriglyceridemia
  - id: HP:0001953
    label: diabetic ketoacidosis
  - id: HP:0001873
    label: thrombocytopenia
  - id: HP:0001882
    label: leukopenia
  - id: HP:0003077
    label: hyperlipidemia
  - id: CHEBI:9168
    label: Sirolimus
  - id: HP:0001735
    label: Acute Pancreatitis
  - id: CHEBI:68554
    label: deferiprone (L1)
  - id: CHEBI:4356
    label: deferoxamine
  - id: HP:0000789
    label: Infertility
  - id: HP:0011134
    label: low-grade fever
  - id: HP:0001974
    label: leukocytosis
  - id: CHEBI:28001
    label: vancomycin
  - id: CHEBI:17833
    label: gentamycin
  - id: MAXO:0000950
    label: supportive care
  - id: MONDO:0004981
    label: Atrial Fibrillation
  - id: HP:0005110
    label: Atrial Fibrillation
  - id: MAXO:0000750
    label: Conditioning regimen
  - id: MONDO:0016820
    label: Moyamoya disease
  - id: HP:0100806
    label: Sepsis
  - id: HP:0001907
    label: Thromboembolism
  - id: HP:0003826
    label: Stillbirth
